Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tonghua Heli Pharmaceutical Co., Ltd. is a pharmaceutical manufacturer based in Tonghua, Jilin Province, China, established in 1994. The company is primarily recognized for its gastrointestinal product portfolio, specifically the probiotic formulation Yi Jun Kang (Compound Lactobacillus Acidophilus Tablets). Yi Jun Kang, which contains Lactobacillus acidophilus, Streptococcus faecalis, and Bacillus subtilis, is widely used in China as an adjuvant therapy to improve the eradication rates of Helicobacter pylori and to manage intestinal dysbiosis. Tonghua Heli operates GMP-certified manufacturing facilities and is a significant contributor to the pharmaceutical industry in the Jilin region. Its products are frequently cited in clinical research for their role in stabilizing the gut microenvironment and reducing the side effects of antibiotic treatments.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on He Li Pharm.